Navigation Links
Bivalirudin, a new anti-clotting drug may be a safer option for treatment of acute coronary conditions

A novel anti-clotting drug named bivalirudin is turning out to be a better option than combination drug therapy for patients suffering heightened //coronary conditions, for instance heart attacks.

Lead researcher Dr. Gregg W. Stone, a professor of medicine and director of cardiovascular research and education at Columbia University said, "We use it at Columbia in the vast majority of cases. We find that compared to heparin, it is just as effective and safely allows us to do angioplasty with a major reduction in bleeding episodes."

During a study involving 14,000 patients, who had suffered heart attack or other acute coronary syndromes, study participants were administered either a treatment including heparin, or a package including bivalirudin or just bivalirudin.It was found that Bivalrudin reduced the occurrence of artery blockage or severe bleeding by nearly 14 percent compared to the effects of a drug package that included Heparin.

"It makes care of patients in the cath lab much simpler and safer. The big difference was the reduction of major bleeding, almost 50 percent. Major bleeding has been associated with higher mortality, so it is important for the outcome", Dr. Gregg W. Stone said.

Dr. John A. Bittl, an interventional cardiologist at the Munroe Regional Medical Center in Ocala, commented, "This report states that bivalirudin can be used for patents with acute coronary syndrome with a lower risk of bleeding than conventional treatment."
'"/>




Page: 1

Related medicine news :

1. Enduring anti-clotting treatment avails heart patients
2. Useful device makes spinal surgery safer
3. Transporter offers reliable clues for safer pain medicine
4. Arthritis drugs safer than previously declared
5. Diet and exercise can be a better option to control diabetes
6. Early detection of alcohol abuse is better option for treatment
7. Children obesity has an option in the form of surgery
8. Substituting soymilk for lactose intolerant students n schools: a great option
9. To cope better with HRT, a good option is Hysterectomies
10. Sweet nothings: A fruitful option to assuage the sweet tooth
11. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: